2015: US Biosimilars’ Year of Reckoning
This year will be one of reckoning for US biosimilars: the four known submissions to the FDA’s biosimilar pathway will between them stress test all aspects of the regulatory framework. The coming months will determine how far FDA can go in support of biosimilars – and how far innovators are prepared go in defense of their portfolios.
You may also be interested in...
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?